Aligos Therapeutics (5WK0) Income Statement
Aligos Therapeutics Income Statement
Last quarter (Q2 2026), Aligos Therapeutics's total revenue was $27.78M, an increase of 2778.55% from the same quarter last year. In Q2, Aligos Therapeutics's net income was $-1.50M. See Aligos Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 2.19M | $ 3.94M | $ 15.53M | $ 13.91M | $ 4.36M | |
| $ 1.26M | $ 3.94M | $ 15.53M | $ 13.91M | $ 4.36M | |
| $ 89.24M | $ 93.10M | $ 103.66M | $ 111.49M | $ 132.68M | |
| Depreciation and Amortization | $ 930.00K | $ 2.62M | $ 3.07M | $ 3.67M | $ 3.78M |
| $ -22.95M | $ -128.26M | $ -83.81M | $ -92.27M | $ -124.41M | |
| $ -87.98M | $ -89.15M | $ -88.13M | $ -97.58M | $ -128.32M | |
| $ 64.11M | $ -41.73M | $ 1.24M | $ 1.64M | $ 132.00K | |
| $ -23.88M | $ -130.88M | $ -86.88M | $ -95.94M | $ -128.19M | |
| $ -24.19M | $ -131.21M | $ -87.68M | $ -96.05M | $ -128.33M | |
| Per Share Metrics | |||||
| Basic EPS | $ -2.45 | $ -20.94 | $ -3.52 | $ -2.25 | $ -3.22 |
| Diluted EPS | $ -2.45 | $ -20.94 | $ -3.52 | $ -2.25 | $ -3.22 |
| Weighted Average Shares Outstanding | 9.88M | 6.26M | 24.87M | 42.70M | 39.86M |
| Weighted Average Shares Outstanding (Diluted) | 9.88M | 6.26M | 24.87M | 42.70M | 39.86M |
Currency in USD
